Elvitegravir/Cobicistat/Emtricitabine/Tenofovir disoproxil fumarate tablets

Hospital Pharmacy

Volumn 48, Issue 1, 2013, Pages 48-56

  Cada, Dennis J ^a   Torres, Silvia ^b   Levien, Terri L ^b   Baker, Danial E ^b  

^a Facts and Comparisons   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ALFUZOSIN; CISAPRIDE; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; DIHYDROERGOTAMINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ERGOTAMINE; HYPERICUM PERFORATUM EXTRACT; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; METHYLERGOMETRINE; MEVINOLIN; MIDAZOLAM; PIMOZIDE; RIFAMPICIN; SILDENAFIL; SIMVASTATIN; TRIAZOLAM;

ABNORMAL DREAMING; ACUTE KIDNEY FAILURE; DIARRHEA; DIZZINESS; DRUG CONTRAINDICATION; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SCREENING; DRUG UTILIZATION; EYE JAUNDICE; FANCONI RENOTUBULAR SYNDROME; FATIGUE; FLATULENCE; HEPATOMEGALY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL PHARMACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INSOMNIA; JAUNDICE; LACTIC ACIDOSIS; NAUSEA; OBESITY; PROTEINURIA; RECOMMENDED DRUG DOSE; REVIEW; SOMNOLENCE; TABLET;

EID: 84873873617     PISSN: 00185787     EISSN: 19451253     Source Type: Journal    
DOI: 10.1310/hpj4801-48     Document Type: Review

References (7)

1. Stribild [package insert]. Foster City, CA: Gilead Sciences Inc; August 2012 Gilead Sciences submits new drug application to FDA for HIV drug [news release]. Foster City, CA: Gilead Sciences Inc; August 26, 2012
2. Antiretroviral agents. Facts & Comparisons [database online]. St. Louis, MO: Wolters Kluwer Health Inc; 2012. Accessed August 31, 2012
3. Cohen C, Elion R, Ruane P, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate versus efavirenz/ emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS. 2011;25(6):F7-F12
4. German P, Warren D, West S, Hui J, Kearney BP. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr. 2010;55(3):323-329
5. DeJesus E, Rockstroh JK, Henry K, et al. GS-236-0103 Study Team. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomized, double-blind, phase 3, non-inferiority trial. Lancet. 2012; 379(9835):2429-2438
6. Sax PE, DeJesus E, Mills A, et al. GS-US-236-0102 Study Team. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomized, double blind, phase 3 trial, analysis of results after 48 weeks [published correction appears in Lancet. 2012; 380(9843):730]. Lancet. 2012;379(9835):2439-2448
7. Cox EM. NDA approval letter: Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate NDA 203100). Food and Drug Administration Web site. http:// www.accessdata.fda.gov/drugsatfda-docs/ appletter/2012/ 0203100Orig1s000ltr.pdf. Published August 27, 2012. Accessed September 5, 2012